Partnering with general practitioners to optimise survivorship for patients with lymphoma: A Phase 2 randomised controlled trial
Project dates:
Commenced: 2020
Completion Due: 2023
Despite good survival outcomes for people diagnosed with, and treated for lymphomas, these people require quality survivorship care. This includes:
- monitoring for cancer recurrence
- surveillance for secondary or new primary cancers
- management of a range of long-term-bio-psycho-social effects from their diagnosis and cancer treatments.
These health concerns highlight the need for a well-integrated, patient-centred model of care for cancer survivors following the completion of cancer treatment.
This prospective, pragmatic randomised controlled trial aims to test the feasibility of the GOSPEL 1 intervention compared to usual care involving Haematologists and General Practitioners for lymphoma shared follow-up survivorship care. Outcomes measured include a range of patient-reported outcomes, safety indicators such as hospital admission and unscheduled lymphoma clinic visits, and process outcomes including the intervention fidelity and economic indicators.
Project outcomes:
This study seeks to demonstrate the feasibility, utility, usefulness, and preliminary efficacy of the new model of shared care between specialists and primary care which could influence lymphoma survivorship follow-up care for cancer survivors.
Funding / Grants
- Health Innovation, Investment and Research Office (HIIRO) Queensland Advancing Clinical Research Fellowships
Chief Investigators
- Adjunct Professor Ray Chan
- Dr Sally Mapp
- Associate Professor Louisa Gordon
- Lee Jones
- Stephanie Buhagiar
- Camilla Simonsen
- Associate Professor Joel Rhee
- Dr Christine Carrington
- Marissa Ryan
